At a glance
ClinicalIndex Comparison RecordN/ACompleted· 31 enrolled
Drug / intervention
Rasburicasedrug
Likely dose
Rasburicase 0.19 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Plasma Uric Acid on Insulin Sensitivity, Endothelial Function and Inflammation
In Brief
A clinical study evaluating Rasburicase for Obesity and 2 related conditions. Completed, enrolled 31 participants across 1 site.
Detailed Summary
The purpose of this study is to learn more about what is the effect of uric acid on oxidative stress and on the way the body metabolizes sugar in obese people. Understanding this may lead to better diseases such as diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Metabolic Syndrome, Hyperuricemia
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
Primary CompletionJun 2008
Study CompletionNov 2012
First PostedAug 2013
TodayJul 2026
First PostedAug 29, 2013
Enrollment StartJul 1, 2006
Primary CompletionJun 1, 2008
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.8 years ago
Interventions
Rasburicasedrug
one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min